Published in final edited form as:

Front Biosci (Schol Ed). ; 4: 916–931.

Insulin resistance, metabolic stress, and atherosclerosis

Meghana Pansuria^{1,2}, Hang Xi^{1,2}, Le Li^{1,4}, Xiao-Feng Yang^{1,2}, and Hong Wang^{1,2,3}

¹Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, 19140

²Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, 19140

³Thrombosis Research Center of Temple University School of Medicine, Philadelphia, PA, 19140

⁴School of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, PR, China

Abstract

Atherosclerosis, a pathological process that underlies the development of cardiovascular disease, is the primary cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). T2DM is characterized by hyperglycemia and insulin resistance (IR), in which target tissues fail to respond to insulin. Systemic IR is associated with impaired insulin signaling in the metabolic tissues and vasculature. Insulin receptor is highly expressed in the liver, muscle, pancreas, and adipose tissue. It is also expressed in vascular cells. It has been suggested that insulin signaling in vascular cells regulates cell proliferation and vascular function. In this review, we discuss the association between IR, metabolic stress, and atherosclerosis with focus on 1) tissue and cell distribution of insulin receptor and its differential signaling transduction and 2) potential mechanism of insulin signaling impairment and its role in the development of atherosclerosis and vascular function in metabolic disorders including hyperglycemia, hypertension, dyslipidemia, and hyperhomocysteinemia. We propose that insulin signaling impairment is the foremost biochemical mechanism underlying increased cardiovascular morbidity and mortality in atherosclerosis, T2DM, and metabolic syndrome.

Keywords

Insulin signaling; Atherosclerosis; Diabetes; Review

2. INTRODUCTION

Diabetes is a group of metabolic diseases marked by high blood glucose levels, either because of insufficient insulin production or impaired biological response to insulin, termed as insulin resistance (IR), a salient feature of type 2 diabetes mellitus (T2DM) (1, 2). It is reported that in the United States 11.3 percentage of adults age 20 years and older have T2DM, this percentage increases to 26.9 percentage in adults age 65 years and older (3). Death rates in adults having diabetes with pre-existing heart disease and stroke are about 2 to 4 times higher than adults without diabetes (4). Systemic IR is associated with impaired vascular insulin signaling (5) and blunted vascular effects of insulin (6). However, the molecular mechanisms linking IR to the development of atherosclerosis remain obscure.

Atherosclerosis is a multifactorial pathological process involving a wide range of cell types and tissues, including vascular, immune, and metabolic cells (7). Similarly, biological actions of insulin are mediated by its binding to cell surface insulin receptor, expressed in nearly every cell type in the body (8). Insulin has numerous effects on peripheral tissues that stimulate glucose uptake. The most sensitive tissues for the insulin-glucose uptake reaction are skeletal muscle and adipose tissue. However, insulin receptor signaling exerts important biological effects on vascular cells and regulates vessel dilation and contraction (9, 10). Moreover, insulin receptor signaling regulates monocyte differentiation into macrophages (11). Certainly, insulin and its receptor are expressed in metabolic organs like the skeletal muscle and pancreas as well as in liver and adipose tissue, which plays an important role in glucose and lipid metabolism (8).

Herein, we describe the tissue and cellular distribution of insulin receptor, and the role of its signaling in physiologic and pathophysiologic conditions. We emphasize the impact of impaired insulin signaling in vascular dysfunction, hypertension, hyperglycemia, dyslipidemia, and other metabolism disorders.

3. INSULIN RECEPTOR SIGNALING

Biological actions of insulin are initiated by its binding to its cell surface receptor, which results in autophosphorylation of the receptor and activation of its intrinsic tyrosine kinase activity (12, 13). The phosphorylated insulin receptor functions as a tyrosine kinase leading to activation of 2 distinct pathways (Figure 1). Via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, it phosphorylates insulin receptor substrate (IRS) family members IRS-1 to 4 (14) at tyrosine residues. Evidence has demonstrated that IRS contains several tyrosine phosphorylation sites and about 50 serine/threonine (Ser/Thr) phosphorylation sites (15). Tyrosine phosphorylation sites such as those found at amino acid positions 608 and 628 (Tyr⁶⁰⁸ and Tyr⁶²⁸); have been shown to positively regulate IRS function. Whereas, Ser/Thr phosphorylation sites such as those found at amino acid positions 307, 612, and 632 (Ser³⁰⁷, Ser⁶¹², and Ser⁶³²) have been shown to negatively regulate IRS function by increasing release of IRS from its internal membrane pools and thus increasing proteosomal degradation. However, evidence shows that Ser/Thr phosphorylation of IRS at amino acid position 789 (Ser⁷⁸⁹), can positively regulate IRS function (16). Thus, the delicate balance that exists between positive tyrosine/serine phosphorylation sites and negative serine phosphorylation sites regulates IRS function (15).

Tyrosine-phosphorylated IRS then binds to the Src homology 2 (SH2) domain-containing adaptor protein p85, a regulatory subunit of PI3K, resulting in activation of the catalytic p110 subunit of PI3K (17, 18). Activated PI3K converts phosphatidylinositol 4, 5-bisphosphate (PIP2) to phosphatidylinositol 3, 4, 5-trisphosphate (PIP3). This initiates a cascade of serine kinases where phosphoinositide dependent kinase-1 (PDK-1) is phosphorylated and activated in order to phosphorylate v-akt murine thymoma viral oncogene (Akt), also known as protein kinase B (PKB), which further phosphorylates and activates downstream substrates (19). This cascade eventually culminates in the pleiotropic biological actions of insulin and contributes to the metabolic action of insulin.

In the parallel mitogen-activated protein kinase (MAPK) pathway, an activated insulin receptor phosphorylates its intracellular substrate SH2 domain-containing alpha-2 collagen-related protein (Shc), which binds to growth factor receptor-bound protein 2 (Grb2), and results in activation of pre-associated guanosine triphosphate (GTP) exchange factor son of sevenless (Sos). Sos further activates the small GTP binding protein Ras, which then initiates a phosphorylation cascade involving Raf, MAPK/extracellular signal-regulated kinase kinase (MEK), and extracellular signal-regulated kinase (Erk). There are two

isoforms of Erk: Erk1 and Erk2 that are ubiquitously expressed. Erk 1/2 are often referred as p42/p44 MAPK (20). Erk1/2 regulates mitogenesis, growth, and differentiation. Apart from Erk1/2, MAPK subfamilies include two other MAPKs; the c-Jun NH2-terminal kinase (JNK) and p38 MAPK. JNK and p38 MAPK are called stress sensitive kinases (21).

JNK protein kinases are encoded by the three genes JNK1, JNK2, and JNK3, which are alternatively spliced to form the JNK isoform (21, 22). The two mitogen-activated protein kinase kinase (MAPKK or MKK) proteins that act as upstream JNK activators are MKK7, which is primarily activated by pro-inflammatory cytokines, and MKK4, which is primarily activated by environmental stress and growth factors. A major JNK target is the transcription factor activator protein-1 (AP-1), which is an important regulator of gene expression (21). JNK protein kinases are involved in the regulation of cell proliferation, differentiation, survival, and migration (22).

The p38 MAPK pathway shares many similarities with the other MAPK pathway, being that it is associated with inflammation, cell proliferation, differentiation, and survival. Four genes are encoded by p38 MAPK, p38 alpha, p38 beta, p38 gamma, and p38 delta. p38 MAPK regulates the expression of many cytokines and is activated in immune cells by inflammatory cytokines. It also has an important role in the activation of immune responses (21, 23). p38 MAPK is also activated by other stimuli including hormones and environmental stress. Moreover, MKK3, MKK6, and MKK4 serve as upstream MAPKs, which are responsible for p38 activation (23).

Emerging evidence suggests that insulin receptor signaling can be enhanced by 5' adenosine monophosphate-activated protein kinase (AMPK), which is a highly conserved Ser/Thr kinase. AMPK is a heterotrimeric complex consisting of a catalytic alpha subunit and regulatory beta and gamma subunits. AMPK is activated under the conditions of hypoxia, glucose deprivation, and ischemia, which deplete cellular adenosine triphosphate (ATP) and increase adenosine monophosphate (AMP) levels, leading to an increase in AMP/ATP ratio (24). It has been reported that exercise, adiponectin and the anti-diabetic drug metformin, can activate AMPK (Figure 1). AMPK activation switches on catabolic pathways that generate ATP, by causing serine phosphorylation of IRS (at amino acid position 789-a positive regulation) (16), endothelial nitric oxide synthase (eNOS) (a positive regulation) (25), and rab-GTPase-activating protein, Akt substrate of 160 kDa (AS160) (a positive regulation) (26); leading to PI3K/Akt activation, nitric oxide (NO) production, and glucose uptake. Whereas, it switches off ATP-consuming anabolic pathways by causing serine phosphorylation of hormone sensitive lipase (HSL) and its inhibition, and threonine phosphorylation of tuberous sclerosis protein 1 and 2 (TSC), leading to anti-lipolysis and inhibition of protein synthesis (27). Due to this background information, AMPK has been suggested to play a role in the pathogenesis of T2DM and thus considered a potential therapeutic target of T2DM. Support for this concept comes from studies using animal models that demonstrate that acute and chronic treatment with the AMPK-activating agent 5-aminoimidazole-4-carboxamide ribofuranoside (AICAR) improves glucose homeostasis and insulin sensitivity (28).

4. INSULIN SIGNALING IN METABOLIC TISSUES

The PI3K/Akt pathway is predominant in the metabolic tissues which controls rapid stimulation of glucose uptake, lipid synthesis, and energy metabolism (Figure 1). Insulin stimulates glucose uptake in muscle and adipocytes via translocation of GLUT4 vesicles to the plasma membrane and induces glycogen synthesis by inhibiting glycogen synthase kinase -3 (GSK-3).

4.1. Pancreas

The islet beta-cells of the pancreas uniquely secrete insulin. Insulin secretion is closely regulated in order to maintain blood glucose levels within a narrow physiological concentration range. Maintenance of the beta-cell mass is a dynamic process which involves an increase (replication/neogenesis) and decrease in the numbers (apoptosis) of beta-cells in order to regulate blood glucose levels within a normal range (29). Numerous pieces of evidence have demonstrated anti-apoptotic role of insulin in the pancreatic beta cells. Insulin activates its own gene (30) and initiates the PI3K/Akt pathway, leading to anti-apoptosis and beta cells survival. Majority of data suggests that beta-cell insulin signaling is essential for insulin exocytosis (31). Study using beta-cell insulin receptor deficient mice, has demonstrated a marked reduction in islet number, beta-cell mass, and insulin secretion (32). It has been shown that beta-cell damage and IR are partially triggered by inflammatory, oxidative, and endoplasmic reticulum stress-induced pathways (33). It is reported that activation of MAPK pathway (JNK (34, 35), p38 MAPK (36), and Erk (37)) promotes insulin resistance, suppresses insulin production, secretion, and increases apoptosis of beta-cells.

Hence, insulin signaling plays an important role in the pancreatic beta cell and resistance to its actions contributes to beta-cell failure, a pathogenesis of T2DM, which leads to consequent glucotoxicity. This is supported by the observations that elevated glucose concentrations induce beta-cell apoptosis in cultured islets from diabetes-prone *Psammomys obesus* (38) and from humans (39, 40). In addition to glucotoxicity, lipotoxicity resulted from insulin signaling impairment in adipocytes, can also cause beta-cell dysfunction (41, 42). Lipotoxicity is commonly observed in the obese, IR, and individuals with T2DM (43). Therefore, at the later stage of T2DM, glucotoxicity and lipotoxicity further apply metabolic stress on beta-cells leading to decreased insulin synthesis and beta-cell dysfunction (44).

4.2. Skeletal muscle, adipose tissue, and liver

Following nutrient intake, plasma glucose triggers pancreatic beta cells to release insulin into the blood. This potent anabolic hormone regulates various post-prandial proceedings. Controlling the cellular localization of the GLUT4 (a family of glucose transporters) in muscle and adipose tissue is crucial in the management of blood glucose homeostasis. Normally, in the basal state this transporter resides in an intracellular membrane compartment. Following insulin stimulation, it rapidly populates the plasma membrane. Arrival of GLUT4 at the plasma membrane leads to cellular glucose influx (Figure 1). Moreover, insulin also suppresses production of glucose and very low-density lipoprotein (VLDL) in the liver (2, 45).

Insulin-induced GLUT4 translocation requires PI3K-mediated signal involving upstream insulin receptor, IRS, downstream Akt, and protein kinase C (PKC) target enzymes, which induces phosphorylation of rab-GTPase-activating protein, AS160, leading to glucose uptake. Metabolic actions of insulin in liver, adipose tissue, and skeletal muscle rely on tyrosine phosphorylation of IRS proteins. Results from specific knockout models have shown that different IRS isoform appear to have specific roles in different tissues. IRS-1 proteins seem to be firmly associated with glucose homeostasis in skeletal muscle, adipose tissues, and pancreatic beta cells (12), while IRS-2 is essential for liver metabolism and beta-cell proliferation (46, 47). IRS-3 appears to play a role in the adipose tissue (46).

Normal metabolic processes in skeletal muscle and adipose tissue include stimulating glucose uptake and in liver inducing glycogen synthesis, reducing glucose production, and its release in to the blood. All of which are impaired in the IR condition (4). Although, other functions of insulin can be affected.

In adipose tissue, insulin reduces the release of free fatty acid (FFA) by PI3K/Akt signaling, results in the HSL inhibition, which hydrolyzes triglycerides to release fatty acids (48). IR leads to increased plasma FFA and consequent lipotoxicity. In addition, FFA induces hepatic glucose generation and reduces muscle glucose uptake, all these contribute to elevated blood glucose levels (49, 50). Moreover, it is reported that the level of plasma adiponectin (secreted by adipose tissue) is reduced in T2DM patients (51), which regulates insulin sensitivity with energy metabolism and serves to link obesity with IR. AMPK activation by exercise, metformin or adiponectin, increased insulin-independent and insulin-dependent muscle glucose uptake (52), fatty acid oxidation (51), and inhibited gluconeogenesis (53), lead to an increase in insulin sensitivity.

Impaired insulin signaling in liver may contribute to elevated plasma FFA levels (50). Increased release of FFA from adipose tissue reduces skeletal muscle FFA uptake. The net consequence of this may be an augmented influx of FFA to the liver, which leads to fatty liver and exacerbates IR (54). In accordance with the above views, insulin actions in metabolic tissues play an essential role in regulating glucose homeostasis (46). The consequent hyperglycemia, dyslipidemia, and inflammation underlie the reciprocal relationships between IR derived atherosclerosis.

5. RELEVANCE OF METABOLIC STRESS WITH IR AND ATHEROSCLEROSIS

IR is a hallmark of metabolic disorders including obesity and T2DM. Multiple metabolic risk factors contribute to the development of IR including: hyperglycemia, increase FFA levels, and hyperhomocysteinemia (HHcy). These risk factors also contribute to endothelial dysfunction-an early event in the atherosclerosis development.

5.1. Hyperglycemia

IR is an initiating pathogenic mechanism in T2DM. When beta cells of the pancreas fail to secrete enough insulin to overcome IR, overt hyperglycemia develops (55). However, hyperglycemia is not only a consequence of, but also an important factor in worsening IR. Studies have demonstrated that hyperglycemia impairs insulin sensitivity and insulin induced Akt/PKB phosphorylation/activation in liver, adipose tissue (56), and skeletal muscle (57), thus causing an increase in hepatic glucose production and impair GLUT4 translocation/glucose uptake. All of these factors thus contribute to IR.

Hyperglycemia impairs both metabolic and vascular actions of insulin through multiple biochemical and cellular mechanisms. These IR derived mechanisms are multiply resourced by the following: 1) elevated oxidative stress, 2) increased flux through polyol and hexosamine biosynthetic pathways, 3) activation of diacylglycerol (DAG) and PKC, 4) formation of advance glycation end-products (AGE). All of these factors then contribute to endothelial dysfunction and accelerate atherosclerotic process (Figure 2). Remarkable evidences have demonstrated an independent relationship between atherosclerosis and glycemic control in patient with T2DM.

Reactive oxygen species (ROS) generated by high glucose impaired, insulin stimulated activation of Akt and eNOS (58). Overexpression of uncoupling protein-1 (UCP-1) or manganese superoxide dismutase (MnSOD) prevents these inhibitory effects of glucose and restores vasodilator actions of insulin (59). Besides impairing insulin signaling pathways, ROS decreases NO bioavailability, reduces cellular tetrahydrobiopterin levels, and promotes generation of superoxide by eNOS (59, 60). In vasculature, increased oxidative stress may impair vessel reactivity, increases vascular smooth muscle cell (VSMC) proliferation,

macrophage adhesion, platelet activation, and lipid peroxidation, which ultimately leads to vascular complications (61).

Hyperglycemia may impair metabolic and vascular actions of insulin by increased flux through the polyol and hexosamine biosynthetic pathway (62, 63). Polyol pathway requires an enzyme aldose reductase. Under normal condition, this enzyme has low affinity for glucose (64). Hyperglycemia increases its activity, leads to an increase in reduction of glucose to sorbitol, which is then oxidized to fructose. This reaction consumes a cofactor nicotinamide adenine dinucleotide phosphate (NADPH), which is an essential cofactor for regenerating a critical intracellular antioxidant, reduced glutathione (64). By reducing the amount of reduced glutathione, the polyol pathway increases susceptibility to intracellular oxidative stress (65).

The hexosamine biosynthetic pathway serves as a nutrient sensor, which plays a role in IR and vascular complications by causing reversible O-linked beta-N-acetylglucosamine (O-GlcNAc) modifications at regulatory serine/threonine phosphorylation sites on proteins involved in insulin signaling pathway. For example, increased O-GlcNAcylation of IRS-1 may lead to reduced insulin-stimulated translocation of GLUT4 and decreased glucose uptake (66, 67).

Hyperglycemia and elevated FFA increase PKC activity by enhancing de novo synthesis of DAG from glucose (68). This increases oxidative stress through activation of NADPH oxidase. It has been shown that increased PKC activity promotes vascular occlusion and vascular inflammation by decreasing NO production and increasing endothelin-1 (ET-1) production (69, 70).

One of the most harmful effects of hyperglycemia is the formation of AGE by the non-enzymatic reaction between glucose and proteins/lipids on the vessel wall (71). Formation of AGE is augmented in the presence of elevated circulating glucose (72). Permanent AGE formation disrupts the molecular confirmation and alters the enzymatic activity. For example, human glycated end-products inhibit insulin-stimulated IRS-1 and IRS-2 tyrosine phosphorylation (73). Furthermore, by binding through its receptor (RAGE) and activating of NADPH oxidase, AGE produces ROS (74). AGE reduces NO bioavailability and eNOS expression by increasing eNOS mRNA degradation (75, 76). AGE also enhances ET-1 expression through the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) (77). Hence, AGE alters the balance between NO and ET-1 favoring vasoconstriction and endothelial dysfunction.

Thus, hyperglycemia contributes to IR and endothelial dysfunction, by inhibiting PI3K/Akt signaling pathway and over-activating MAPK signaling pathway.

5.2. Dyslipidemia

Increase in plasma FFA levels contributes to IR, by inhibiting glucose transport and/or phosphorylation with a subsequent reduction in the rates of glucose oxidation and muscle glycogen synthesis (78). Cross-sectional study of young, normal-weight offspring of T2DM patients, have demonstrated an inverse relationship between fasting plasma fatty acid levels and insulin sensitivity, which suggest that altered fatty acid metabolism contributes to IR (79). Excess FFA increases ROS generation, which can also contribute in the pathogenesis of IR (80).

IR has been implicated in promoting dyslipidemia, a well established risk factor of CVD. Dyslipidemia is characterized by hypertriglyceridemia, elevated blood levels of apolipoprotein B, small, dense low-density lipoprotein (LDL) cholesterol, and low high-

density lipoprotein (HDL) cholesterol levels. High circulating FFA levels enhances glucose output from the liver and reduces glucose disposal in skeletal muscle, thereby contributing to IR. The role of elevated circulating FFA has been emphasized as a major factor that connects IR and dyslipidemia (1). Moreover, increased FFA stimulates liver to assemble VLDL. Increased plasma levels of VLDL, accelerate VLDL accumulation in the blood vessel wall, followed by higher levels of small, dense LDL. They consequently deliver amounts of cholesterol to the vessel wall, directly bound to proteoglycans within the extracellular matrix and can thereby contribute to plaque formation (49).

Elevated cellular levels of lipid metabolites such as DAG, ceramide, and long-chain fatty acyl CoAs activate PKC and inhibitor of nuclear factor kappa B kinase beta subunit (IKKbeta) leading to serine phosphorylation of IRS-1 at amino acid position 307 (a negative regulation) and inhibit IRS-1 tyrosine phosphorylation in the skeletal muscle (81) and endothelial cell (EC) (82). FFA increases ROS generation and impairs insulin/PI3K/PDK1/Akt/eNOS pathway in EC (Figure 2) (83, 84). FFA infusion intensifies insulin mediated ET-1 release in IR individuals (85). Diminishing forearm lipid oxidation decreases insulin-mediated ET-1 release whereas concurrently increasing NO bioavailability and glucose uptake (86).

5.3. Hyperhomocysteinemia (HHcy)

An elevated plasma level of homocysteine (Hcy) is an independent risk factor for CVD (87). Hcy, a sulfhydryl-containing amino acid, is a metabolite of methionine. Metabolism of Hcy occurs through 2 pathways. Remethylation pathways to methionine, catalyzed by enzymes methionine synthase and methylene tetrahydrofolate reductase (MTHFR) and transsulfuration pathway to cysteine, catalyzed by enzyme cystathionine beta synthase (CBS) - a pyridoxine (vitamin B6) dependent enzyme. Both folic acid and cobalamin (vitamin B12) are important co-factors in remethylation reaction. Hereditary enzyme deficiency, nutritional deficiency of folate, pyridoxine, and cobalamin are associated with elevated blood levels of Hcy and accelerate atherosclerosis (87). It has been shown that HHcy increases oxidant stress, platelet aggregation, enhances activation of coagulation system, VSMC proliferation, and inhibit EC proliferation (88–90). IR has been suggested to arise from similar mechanism and may be possible link between HHcy and atherosclerosis (91).

It has been demonstrated that insulin resistant T2DM patients with CVD have elevated plasma Hcy levels (92). Furthermore, it is reported that acute hyperinsulinemia leads to increased plasma Hcy levels in obese IR patients (93–95). A recent clinical study observed that IR and endothelial function are improved in patients with metabolic syndrome after folate and vitamin B12 therapy (96). This study suggested that prolonged folate administration decreases Hcy and reduces insulin levels, thereby improving IR.

Studies in cultured hepatoma cells indicated that Hcy thiolactone inhibit insulin signaling and it's action by increasing oxidative stress (97, 98). In a separate study using mouse hepatocytes indicated that hyperinsulinemia causes HHcy by decreasing activity of Hcy metabolizing enzymes such as MTHFR and CBS (99, 100). Furthermore, in a study using rats fed with high fat and sucrose diet, has developed obesity which is associated with hyperinsulinemia, IR, and HHcy, along with changes in CBS and MTHFR enzymes in liver (101). These studies suggest that HHcy may cause IR, or vice versa, and that this HHcy and IR connection play important role in the development of CVD. The relationship between Hcy and IR is still ambiguous and complicated, remain to be uncovered.

6. INSULIN SIGNALING IN VASCULAR CELLS (FIGURE 2)

Briefly, atherosclerosis is initiated by endothelial injury and VSMC proliferation, and then injured EC will attract monocytes attending and adhering to endothelium. Loss of EC will also expose intimae to blood stream and activate platelets. That promotes monocytes differentiation to macrophages and then macrophages engorge with oxidized low-density lipoprotein to generate foam cells, finally build atheroma beneath the endothelial monolayer (102).

6.1. Endothelial cells (ECs)

Insulin receptors were initially identified and characterized by ^{125}I -insulin receptor binding studies in human umbilical vein endothelial cell (HUVEC) (103). In recent years, a complete insulin signaling pathway leading to phosphorylation and activation of eNOS has been elucidated in EC. It has been established that insulin is a vasoactive hormone (6), which stimulates production of NO in EC (6, 104) via IRS/PI3K/Akt pathway (69, 105). This reaction can be blunted in presence of PI3K-inhibitors, wortmannin and LY294002 (69). Down-regulation of Ras, an upstream mediator of MAPK signaling has little effect on insulin-induced NO production in EC (106, 107). Insulin-induced NO production amplifies blood flow and functional capillary recruitment to peripheral tissues. These result in increased delivery of insulin and glucose to skeletal muscle and adipose tissue, which contributes to insulin-mediated glucose uptake. In contrast, impaired insulin signaling inhibits NO production, vascular reactivity, and reduces the delivery of glucose and insulin to the peripheral tissues. It is reported that adiponectin expression is reduced in the aorta of leptin receptor-deficient db/db mice (T2DM mouse model) (108). Adiponectin protects against endothelial dysfunction by activating AMPK and producing NO. Moreover, it has demonstrated that AMPK activation reduces oxidative stress and improves endothelial function in hyperglycemic condition (109).

Insulin can also activate MAPK-dependent signaling pathway, which regulates secretion of the vasoconstrictor ET-1 from endothelium. MAPK pathway regulates biological actions related to growth, mitogenesis, and differentiation (110, 111). Studies in bovine aortic EC (BAEC) and in rat mesenteric arteries have confirmed that insulin acutely stimulates ET-1 secretion via MAPK-dependent signaling pathway (112).

Moreover, insulin stimulates phosphorylation of the alpha subunit of farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase), and activities of both prenyltransferases in EC (113). Activation of FTase and GGTase cause the prenylation of Ras and Rho proteins, which are increased in the aorta and liver of IR humans and animals. Prenylated Ras and Rho proteins are associated with increased mitogenetic responses (114, 115). Collectively, impaired insulin-PI3K and -MAPK signaling in EC contributes to endothelial dysfunction in T2DM.

6.2. Vascular smooth muscle cells (VSMCs)

The presence of insulin receptor was demonstrated by ^{125}I -insulin binding studies in cultured human aortic smooth muscle cells (HASMC) (116). The number of insulin receptors is 10-fold lower in bovine aortic smooth muscle cell (BASMC) compared with BAEC (116). Both insulin and insulin-like growth factor-1 receptors (IGF-1R) are present on rat aortic smooth muscle cell (RASMC), and these receptors are distinct from each other in terms of binding affinity of insulin and IGF-1 (117). Insulin receptors on VSMC are structurally and functionally similar to those in metabolic tissues (8, 118). However, VSMC and metabolic cells use different types of glucose transporter, GLUT1 in VSMC and GLUT4 in skeletal muscle (119).

It has been shown that insulin maintains VSMC quiescence and differentiation via PI3K-dependent pathway. The MAPK-dependent signaling pathway controls proliferation and migration (120, 121). A MEK1/2 inhibitor, PD98059 blocked the mitogenic responses to insulin (121) and PI3K inhibitor; wortmannin reversed quiescent status in VSMC (120). In vasculature, bioavailable NO mainly originates from endothelium. Endothelium-derived NO diffuses into VSMC where it activates guanylate cyclase, which augments cyclic guanosine monophosphate (cGMP) levels that leads to vasorelaxation. Insulin increases NOS activity (eNOS and iNOS) and NO dependent cGMP production in VSMC (122, 123). Both genistein (a tyrosine kinase inhibitor) and wortmannin (a PI3K-inhibitor) block insulin-induced NO production in VSMC, suggesting that the insulin receptor tyrosine kinase and subsequent activation of PI3K are both necessary for insulin-induced eNOS or iNOS activation in VSMC (122).

In general, insulin has anti-atherogenic, anti-inflammatory, and anti-thrombotic effects, and these effects are reversed or blunted in the IR state.

7. RELEVANCE OF IR IN VASCULAR CELLS WITH ATHEROSCLEROSIS

Increasing evidence has suggested an association of hyperinsulinemia with the development of atherosclerosis in diabetics. Endothelial dysfunction, an early event of atherosclerosis, has been documented in the IR states in animals and humans (124, 125). PI3K/Akt pathway is blunted in IR states, leads to eNOS inactivation and reduces NO production in EC (5, 126). Mitogenic MAPK pathway in EC and VSMC remains intact and its associated cell effects may in fact be enhanced (112, 127). The blunted PI3K/Akt signaling and enhanced MAPK signaling contributes to impaired vascular function, leading to further atherogenesis (Figure 2). This is supported by human studies which demonstrate that insulin infusion in healthy individuals stimulates vasodilation and increases blood flow to the peripheral tissues (11, 124, and 128). These effects are blunted in the IR and T2DM individuals (11, 124, and 128). A study using in vitro model of metabolic IR (by blocking PI3K/Akt-dependent signaling) with compensatory hyperinsulinemia (by exposing cells to high insulin concentration) in endothelium, shows decreased eNOS protein expression and NO production (113). While increased prenylation of Ras and Rho proteins via MAPK-dependent signaling, with increased expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule (VCAM), and E-selection in EC, and increased rolling interactions of monocytes with EC (8). Impaired insulin receptor autophosphorylation, IRS-1 tyrosine phosphorylation, associated PI3K activity, and Akt activity was observed in blood vessels from homozygous Zucker fatty rats (a model of obesity-related IR) (104). However, MAPK phosphorylation was not changed (104). Reduced eNOS expression and NO production are found in aorta from endothelial cell specific insulin receptor knockout mice and in mice with dysfunctional insulin receptor (Thr1134 substituted with Ala in the kinase domain) (129). Moreover, IR is accompanied with impaired endothelium-dependent vasodilation in IRS-1 deficient mice (130). It has been shown that AMPK counteract the stress induced IR by increasing insulin induced IRS/PI3K/eNOS pathway (Figure 2) (16, 25). These contribute in improving IR and vascular function in T2DM.

Furthermore, in a study using insulin receptor and apolipoprotein E (ApoE) deficient mice indicated that endothelial IR may accelerate atherosclerosis by causing impaired eNOS activation, increased endothelial VCAM expression, and increased leukocyte interaction with EC (131). It is also of interest to determine whether the converse is true, whether endothelial dysfunction inherently confers IR. This is supported by the study using both eNOS and iNOS mouse knockout models (132). Short-term insulin infusion under isoglycemic condition modestly decreases or has no effect on arterial blood pressure. However, hypertension (high blood pressure) occurs in IR, increases fluid volume, arterial

stiffness, and even impaired insulin handling, leading to narrowed lumen diameter, which contributes to the development of atherosclerosis (133).

Several mechanisms have been proposed to explain the contribution of impaired insulin signaling in VSMC to atherosclerosis. These include promoting VSMC proliferation and migration, increased extracellular matrix proteins expression, and inducing apoptosis. Hyperglycemia increases PKC activity, NF-kappaB production, and generation of oxygen-derived free radicals in cultured VSMC (134), and heightens the migration of VSMC into nascent atherosclerotic lesions (135). T2DM patients tend to have fewer VSMC in the lesions, which increases the propensity for the plaque rupture (136), and increases vessel wall cytokines, which diminish VSMC, decrease collagen, and increase matrix metalloproteinases, yielding an increased propensity for plaque destabilization and rupture (137).

8. INSULIN SIGNALING IN IMMUNE CELLS

Individuals with T2DM have overly active immune responses, leaving their bodies rife with inflammatory chemicals. On the contrary, IR could also cause inflammation. Inflammatory responses-inflammation is a complex stereotypical reaction of the body, causing damage of its cells and vascularized tissues.

8.1. Monocytes/Macrophages

Monocytes and macrophages are the basic cell types of mononuclear phagocytic system. These are involved in all stages of the immune response. Insulin signaling in macrophages leads to increase in viability, protein synthesis and secretion, and phagocytosis (138).

Insulin activates IRS/PI3K/Akt signaling in monocytes/macrophages, similar to that in the vascular cells and metabolic tissues except that IRS-1 isoform is undetectable in monocytes/macrophages (139, 140). Decreased insulin receptor/IRS-1/2 tyrosine phosphorylation, and reduction in downstream signaling was observed in macrophages from obese, insulin-resistant mice (139) and monocytes from obese subjects (141).

Macrophage apoptosis in atherosclerotic lesions may add further to the monocyte recruitment, by the release of cytokines and may therefore, exacerbate the advancement of vascular lesion (142–144). It has been shown that insulin increases anti-apoptotic gene Bcl-x expression and leads to reduction in apoptosis in macrophages differentiated from monocytic THP-1 cell line (145), which is repressed by PI3K inhibitor (145). This study has demonstrated that in IR state, the defensive function of insulin to reduce macrophage apoptosis may be lost as the PI3K pathway is blunted under these conditions.

8.2. T lymphocytes

Lymphocytes and leukocytes are the cellular components of inflammation, which normally reside in blood and must extravasate the inflamed tissue to aid in inflammation. Chronic inflammation is mediated by mononuclear cells including lymphocytes and monocytes (8).

Unlike monocytes, circulating T lymphocytes do not have insulin receptors. However, T lymphocytes have the atypical capability to express insulin receptors following presentation of an antigen in vivo and an antigen or mitogen in vitro (146), which activate IRS/PI3K/Akt signaling (147) and increase glucose uptake (148).

Similar to monocytes, T lymphocytes adhere and infiltrate across the vascular endothelium into the subendothelial space, where they are immunologically active (149). In patients with T2DM, a product of proinsulin C-peptide, which is increased in insulin-resistant subjects,

colocalizes with CD4⁺ T lymphocytes in atherosclerotic lesions and acts as a chemotactic stimulus for T lymphocytes to adhere and penetrate the vessel wall (150).

9. RELEVANCE OF IR IN IMMUNE CELLS WITH ATHEROSCLEROSIS

Remarkable evidences have demonstrated that atherosclerotic process is regulated by inflammatory mechanisms (151, 152). Vascular endothelium is both affected by and contributes to the inflammatory process. Besides, IR has been progressively associated with inflammatory state (153–155); it may impair endothelial function and contributes to atherosclerosis.

In atherosclerosis, macrophage activation/T lymphocytes infiltration secretes pro-inflammatory cytokines and cytotoxic substances (156), which play a role in the initiation of atherosclerotic lesion (157). Epidemiological evidences demonstrated that patients with T2DM or obesity have augmented circulating levels of inflammatory markers, including C-reactive protein (CRP), TNF-alpha, interleukin-6, and ICAM-1 (124, 158). These will predict cardiovascular risk in individuals having diabetes (159). CRP (157) and pro-inflammatory cytokine TNF-alpha (158) have been shown to reduce eNOS activation, increase VCAM and ICAM-1 expression, adhesion of monocytes to the EC, and impair endothelium-dependent vasodilation in both animal and human studies (159). Moreover, TNF-alpha induces EC apoptosis by impairing Akt phosphorylation (160).

It has been demonstrated that FFA, inflammatory cytokines and the RAGE (161, 162) activate transcription factor NF-kappaB, a key regulator of endothelial activation and linked to the pathogenesis of IR (160, 163). NF-kappaB activation involves phosphorylation, ubiquitination, and subsequent degradation of the inhibitory subunit Ikb (by Ikb kinase). It allows translocation of the regulatory subunits p50 and p65 to the nucleus, where they promote transcriptional expression of inflammatory genes. Genetic suppression or pharmacological inhibition of IKKbeta with salicylates was demonstrated to prevent IR (160, 164). Several in vitro and in vivo studies using animal models and human studies support the relevance between NF-kappaB activation, progression of inflammatory phenotype, IR, and impaired bioactivity of NO (82, 165).

10. SUMMARY

IR is commonly observed in the metabolic syndrome, in which multiple metabolic risk factors are co-existed including abdominal obesity, hyperglycemia, hyperinsulinemia, dyslipidemia, hypertension, and hyperhomocysteinemia. Patients with the metabolic syndrome are at increased risk of developing coronary heart disease, stroke, and T2DM. The prevalence of metabolic syndrome is estimated to be up to 25 percentage of the population in the United States, and increases with age. In this review, insulin receptor is chosen to connect these individual clinical manifestations. This is based on its ubiquitous expression in cell/tissue and its function in regulating the metabolisms (glucose, lipid, and insulin) and in modulating basic cellular function (cell proliferation and apoptosis), and in controlling NO production. IR in metabolic tissues leads to metabolic disorders, in vascular cells it results in vessel compliance impairment, and in immune cells it causes inflammation initiation, which all contribute to the development of atherosclerosis (Figure 3). Future studies to identify molecular basis of impaired insulin signaling in different tissues would lead to the discovery of novel therapeutic strategies for IR-related metabolism syndrome to reduce the risk of cardiovascular disease.

References

1. Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. *Diabetes*. 1991; 40:166–180. [PubMed: 1991568]
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet*. 2005; 365:1415–1428. [PubMed: 15836891]
3. American diabetes association. 2011. <http://www.diabetes.org/diabetes-basics/diabetes-statistics/>
4. Petersen KF, Shulman GI. Etiology of insulin resistance. *Am J Med*. 2006; 119:S10–S16. [PubMed: 16563942]
5. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. *J Clin Invest*. 1999; 104:447–457. [PubMed: 10449437]
6. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. *J Clin Invest*. 1994; 94:1172–1179.
7. Ross R. Cell biology of atherosclerosis. *Annu Rev Physiol*. 1995; 57:791–804. [PubMed: 7778883]
8. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. *Endocr Rev*. 2006; 27:242–259. [PubMed: 16492903]
9. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. *Lancet*. 1997; 350(Suppl 1):SI9–SI13. [PubMed: 9250277]
10. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. *Am J Med*. 2004; 117:109–117. [PubMed: 15234647]
11. Malide D, Davies-Hill TM, Levine M, Simpson IA. Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation. *Am J Physiol*. 1998; 274:E516–E526. [PubMed: 9530136]
12. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. *Nature*. 2001; 414:799–806. [PubMed: 11742412]
13. Nystrom FH, Quon MJ. Insulin signaling: metabolic pathways and mechanisms for specificity. *Cell Signal*. 1999; 11:563–574. [PubMed: 10433517]
14. White MF. IRS proteins and the common path to diabetes. *Am J Physiol Endocrinol Metab*. 2002; 283:E413–E422. [PubMed: 12169433]
15. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. *Biochimie*. 2005; 87:99–109. [PubMed: 15733744]
16. Qiao LY, Zhande R, Jetton TL, Zhou G, Sun XJ. In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. *J Biol Chem*. 2002; 277:26530–26539. [PubMed: 12006586]
17. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. *Biochem J*. 1998; 333(Pt 3):471–490. [PubMed: 9677303]
18. Cantley LC. The phosphoinositide 3-kinase pathway. *Science*. 2002; 296:1655–1657. [PubMed: 12040186]
19. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. *Biochem J*. 2000; 346(Pt 3):561–576. [PubMed: 10698680]
20. Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, Charron J, Khavari PA. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. *Dev Cell*. 2007; 12:615–629. [PubMed: 17419998]
21. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. *Science*. 2002; 298:1911–1912. [PubMed: 12471242]
22. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. *Nat Rev Cancer*. 2009; 9:537–549. [PubMed: 19629069]
23. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. *Nat Rev Drug Discov*. 2003; 2:717–726. [PubMed: 12951578]
24. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. *Endocrinology*. 2003; 144:5179–5183. [PubMed: 12960015]

25. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. *J Biol Chem*. 2003; 278:45021–450216. [PubMed: 12944390]
26. Jessen N, Pold R, Buhl ES, Jensen LS, Schmitz O, Lund S. Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. *J Appl Physiol*. 2003; 94:1373–1379. [PubMed: 12496137]
27. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. *Trends Mol Med*. 2008; 14:539–549. [PubMed: 18977694]
28. Hojlund K, Mustard KJ, Staehr P, Hardie DG, Beck-Nielsen H, Richter EA, Wojtaszewski JF. AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes. *Am J Physiol Endocrinol Metab*. 2004; 286:E239–E244. [PubMed: 14532170]
29. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. *Diabetes*. 2004; 53(Suppl 3):S16–21. [PubMed: 15561905]
30. Okada T, Liew CW, Hu J, Hinault C, Michael MD, Krtzfeldt J, Yin C, Holzenberger M, Stoffel M, Kulkarni RN. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. *Proc Natl Acad Sci U S A*. 2007; 104:8977–8982. [PubMed: 17416680]
31. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell*. 1999; 96:329–339. [PubMed: 10025399]
32. Otani K, Kulkarni RN, Baldwin AC, Krutzfeldt J, Ueki K, Stoffel M, Kahn CR, Polonsky KS. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. *Am J Physiol Endocrinol Metab*. 2004; 286:E41–E49. [PubMed: 14519599]
33. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006; 444:860–867. [PubMed: 17167474]
34. Kajimoto Y, Kaneto H. Role of oxidative stress in pancreatic beta-cell dysfunction. *Ann N Y Acad Sci*. 2004; 1011:168–176. [PubMed: 15126294]
35. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. *Nature*. 2002; 420:333–336. [PubMed: 12447443]
36. Sumara G, Formentini I, Collins S, Sumara I, Windak R, Bodenmiller B, Ramacheya R, Caille D, Jiang H, Platt KA, Meda P, Aebersold R, Rorsman P, Ricci R. Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. *Cell*. 2009; 136:235–248. [PubMed: 19135240]
37. Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, Mandrup-Poulsen T, Donath MY. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca²⁺ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K⁺ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. *Diabetes*. 2004; 53:1706–1713. [PubMed: 15220194]
38. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of *Psammomys obesus* during development of diabetes. *Diabetes*. 1999; 48:738–744. [PubMed: 10102689]
39. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. *Diabetes*. 2001; 50:1290–1301. [PubMed: 11375329]
40. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes*. 2003; 52:102–110. [PubMed: 12502499]
41. El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, Rosenberg L, Prentki M. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. *Endocrinology*. 2003; 144:4154–4163. [PubMed: 12933690]

42. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, Marchetti P. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. *Diabetes*. 2002; 51:1437–1442. [PubMed: 11978640]
43. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006; 444:840–846. [PubMed: 17167471]
44. Piro S, Anello M, Di Pietro C, Lizzio MN, Patane G, Rabuazzo AM, Vigneri R, Purrello M, Purrello F. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. *Metabolism*. 2002; 51:1340–1347. [PubMed: 12370856]
45. Yki-Jarvinen H. Nonglycemic effects of insulin. *Clin Cornerstone Suppl*. 2003; 4:S6–S12.
46. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H, Satoh S, Sekihara H, Sciacchitano S, Lesniak M, Aizawa S, Nagai R, Kimura S, Akanuma Y, Taylor SI, Kadowaki T. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. *Diabetes*. 2000; 49:1880–1889. [PubMed: 11078455]
47. Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. *Diabetologia*. 2004; 47:170–184. [PubMed: 14722654]
48. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. *J Clin Invest*. 1994; 93:2438–2446. [PubMed: 8200979]
49. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. *Am J Physiol Endocrinol Metab*. 2002; 283:E12–E19. [PubMed: 12067837]
50. Boden G. Gluconeogenesis and glycogenolysis in health and diabetes. *J Investig Med*. 2004; 52:375–378.
51. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci U S A*. 2001; 98:2005–2010. [PubMed: 11172066]
52. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med*. 2002; 8:1288–1295. [PubMed: 12368907]
53. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med*. 2001; 7:947–953. [PubMed: 11479628]
54. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. *Clin Chim Acta*. 2006; 368:1–19. [PubMed: 16480697]
55. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. *Diabetes Care*. 1990; 13:610–630. [PubMed: 2192847]
56. Nawano M, Oku A, Ueta K, Umebayashi I, Ishirahara T, Arakawa K, Saito A, Anai M, Kikuchi M, Asano T. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. *Am J Physiol Endocrinol Metab*. 2000; 278:E535–E543. [PubMed: 10710509]
57. Pouwels MJ, Span PN, Tack CJ, Olthaar AJ, Sweep CG, van Engelen BG, de Jong JG, Lutterman JA, Hermus AR. Muscle uridine diphosphate-hexosamines do not decrease despite correction of hyperglycemia-induced insulin resistance in type 2 diabetes. *J Clin Endocrinol Metab*. 2002; 87:5179–5184. [PubMed: 12414889]
58. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. *Circulation*. 2002; 106:987–92. [PubMed: 12186805]
59. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. *J Clin Invest*. 2001; 108:1341–1348. [PubMed: 11696579]

60. Schnyder B, Pittet M, Durand J, Schnyder-Candrian S. Rapid effects of glucose on the insulin signaling of endothelial NO generation and epithelial Na transport. *Am J Physiol Endocrinol Metab.* 2002; 282:E87–E94. [PubMed: 11739088]
61. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. *Curr Atheroscler Rep.* 1999; 1:156–164. [PubMed: 11122705]
62. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes.* 2005; 54:1615–1625. [PubMed: 15919781]
63. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. *Am J Physiol Endocrinol Metab.* 2006; 290:E1–E8. [PubMed: 16339923]
64. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature.* 2000; 404:787–790. [PubMed: 10783895]
65. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. *Diabetes.* 1998; 47:945–952. [PubMed: 9604873]
66. Ball LE, Berkaw MN, Buse MG. Identification of the major site of O-linked beta-N-acetylglucosamine modification in the C terminus of insulin receptor substrate-1. *Mol Cell Proteomics.* 2006; 5:313–23. [PubMed: 16244361]
67. Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, Garvey WT. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. *J Clin Invest.* 1995; 96:2792–2801. [PubMed: 8675649]
68. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. *Diabetes.* 2000; 49:1939–1945. [PubMed: 11078463]
69. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. *Circulation.* 2000; 101:676–6810. [PubMed: 10673261]
70. King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. *Histochem Cell Biol.* 2004; 122:333–338. [PubMed: 15257460]
71. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation.* 2006; 114:597–605. [PubMed: 16894049]
72. Wold LE, Ceylan-Isik AF, Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. *Acta Pharmacol Sin.* 2005; 26:908–917. [PubMed: 16038622]
73. Miele C, Riboulet A, Maitan MA, Oriente F, Romano C, Formisano P, Giudicelli J, Beguinot F, Van Obberghen E. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. *J Biol Chem.* 2003; 278:47376–47387. [PubMed: 12970360]
74. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. *Am J Physiol Endocrinol Metab.* 2001; 280:E685–E694. [PubMed: 11287350]
75. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. *Circ Res.* 1999; 84:489–497. [PubMed: 10082470]
76. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. *Circ Res.* 2000; 86:E50–E54. [PubMed: 10679490]
77. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. *Diabete.* 2000; 49:1561–1570.

78. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. *Eur J Clin Invest.* 2002; 32(Suppl 3): 14–23. [PubMed: 12028371]
79. Shulman GI. Cellular mechanisms of insulin resistance. *J Clin Invest.* 2000; 106:171–176. [PubMed: 10903330]
80. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. *Clin Cornerstone.* 2007; 8(Suppl 7):S30–S42. [PubMed: 18154189]
81. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *J Biol Chem.* 2002; 277:50230–50236. [PubMed: 12006582]
82. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, Baas AS, Paramsothy P, Giachelli CM, Corson MA, Raines EW. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. *Arterioscler Thromb Vasc Biol.* 2005; 25:989–994. [PubMed: 15731493]
83. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. *J Clin Invest.* 2006; 116:1071–1080. [PubMed: 16528409]
84. Kim YB, Shulman GI, Kahn BB. Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3. *J Biol Chem.* 2002; 277:32915–32922. [PubMed: 12095990]
85. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. *Diabetes.* 1996; 45:316–321. [PubMed: 8593936]
86. Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, Origgi A, Margonato A, Piatti P. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. *Am J Physiol Endocrinol Metab.* 2006; 290:E54–E59. [PubMed: 16174656]
87. Wang H, Tan H, Yang F. Mechanisms in homocysteine-induced vascular disease. *Drug Discovery Today: Disease Mechanisms.* 2005; 2:25–31.
88. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, Haber E, Chang TH, Schlegel R, Lee ME. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. *J Clin Invest.* 1996; 97:146–153. [PubMed: 8550827]
89. Lee ME, Wang H. Homocysteine and Hypomethylation: A Novel Link to Vascular Disease. *Trends in Cardiovascular Medicine.* 1999; 9:49–54. [PubMed: 10189967]
90. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. *Am J Physiol Heart Circ Physiol.* 2005; 289:H2649–H2656. [PubMed: 16085680]
91. Oron-Herman M, Rosenthal T, Sela BA. Hyperhomocysteinemia as a component of syndrome X. *Metabolism.* 2003; 52:1491–1495. [PubMed: 14624412]
92. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, Kosaka S, Takahashi S, Miyamori I. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. *Diabetes Care.* 1999; 22:484–490. [PubMed: 10097933]
93. Sanchez-Margalet V, Valle M, Ruz FJ, Gascon F, Mateo J, Goberna R. Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects. *J Nutr Biochem.* 2002; 13:75–79. [PubMed: 11834222]
94. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D'Agostino RB Sr, Wilson PW. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. *Diabetes Care.* 2001; 24:1403–1410. [PubMed: 11473077]
95. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. *Atherosclerosis.* 1998; 139:197–198. [PubMed: 9699908]
96. Setola E, Monti LD, Galluccio E, Palloshi A, Fragasso G, Paroni R, Magni F, Sandoli EP, Lucotti P, Costa S, Fermo I, Galli-Kienle M, Origgi A, Margonato A, Piatti P. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic

- syndrome: relationship between homocysteine levels and hyperinsulinemia. *Eur J Endocrinol.* 2004; 151:483–489. [PubMed: 15476449]
97. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. *J Mol Endocrinol.* 2001; 27:85–91. [PubMed: 11463579]
 98. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. *J Mol Endocrinol.* 2005; 34:119–126. [PubMed: 15691882]
 99. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. *Diabetes.* 1998; 47:1967–1970. [PubMed: 9836532]
 100. Dicker-Brown A, Fonseca VA, Fink LM, Kern PA. The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. *Atherosclerosis.* 2001; 158:297–301. [PubMed: 11583707]
 101. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L, Kern PA. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. *Metabolism.* 2000; 49:736–741. [PubMed: 10877198]
 102. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med.* 1999; 340:115–126. [PubMed: 9887164]
 103. Bar RS, Hoak JC, Peacock ML. Insulin receptors in human endothelial cells: identification and characterization. *J Clin Endocrinol Metab.* 1978; 47:699–702. [PubMed: 400730]
 104. Montagnani M, Quon MJ. Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension. *Diabetes Obes Metab.* 2000; 2:285–292. [PubMed: 11225743]
 105. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. *Circulation.* 2000; 101:1539–1545. [PubMed: 10747347]
 106. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca²⁺ but requires phosphorylation by Akt at Ser (1179). *J Biol Chem.* 2001; 276:30392–30398. [PubMed: 11402048]
 107. Hartell NA, Archer HE, Bailey CJ. Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B. *Biochem Pharmacol.* 2005; 69:781–790. [PubMed: 15710355]
 108. Zhang H, Park Y, Zhang C. Coronary and aortic endothelial function affected by feedback between adiponectin and tumor necrosis factor alpha in type 2 diabetic mice. *Arterioscler Thromb Vasc Biol.* 2010; 30:2156–21563. [PubMed: 20814014]
 109. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, Scalia R, Goldstein BJ. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. *Diabetes.* 2006; 55:1840–18406. [PubMed: 16731851]
 110. Nacci C, Tarquinio M, Montagnani M. Molecular and clinical aspects of endothelial dysfunction in diabetes. *Intern Emerg Med.* 2009; 4:107–116. [PubMed: 19280353]
 111. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. *Diabet Med.* 2003; 20:255–268. [PubMed: 12675638]
 112. Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. *Diabetes.* 2006; 55:3594–35603. [PubMed: 17130509]
 113. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. *J Biol Chem.* 2002; 277:1794–1799. [PubMed: 11707433]

114. Goalstone ML, Wall K, Leitner JW, Kurowski T, Ruderman N, Pan SJ, Ivy JL, Moller DE, Draznin B. Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals. *Diabetologia*. 1999; 42:310–316. [PubMed: 10096783]
115. Draznin B, Miles P, Kruszynska Y, Olefsky J, Friedman J, Golovchenko I, Stjernholm R, Wall K, Reitman M, Accili D, Cooksey R, McClain D, Goalstone M. Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia. *Endocrinology*. 2000; 141:1310–1316. [PubMed: 10746633]
116. King GL, Buzney SM, Kahn CR, Hetu N, Buchwald S, Macdonald SG, Rand LI. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. *J Clin Invest*. 1983; 71:974–979. [PubMed: 6339562]
117. Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. *Diabetologia*. 1991; 34:307–313. [PubMed: 1713869]
118. Jialal I, Crettaz M, Hachiya HL, Kahn CR, Moses AC, Buzney SM, King GL. Characterization of the receptors for insulin and the insulin-like growth factors on micro- and macrovascular tissues. *Endocrinology*. 1985; 117:1222–1229. [PubMed: 2990869]
119. Klip A, Tsakiridis T, Marette A, Ortiz PA. Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. *Faseb J*. 1994; 8:43–53. [PubMed: 8299889]
120. Wang CC, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. *Diabetes*. 2003; 52:2562–2569. [PubMed: 14514641]
121. Xi XP, Graf K, Goetze S, Hsueh WA, Law RE. Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. *FEBS Lett*. 1997; 417:283–286. [PubMed: 9409734]
122. Begum N, Ragolia L, Rienzie J, McCarthy M, Duddy N. Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension. *J Biol Chem*. 1998; 273:25164–25170. [PubMed: 9737976]
123. Trovati M, Massucco P, Mattiello L, Costamagna C, Aldieri E, Cavalot F, Anfossi G, Bosia A, Ghigo D. Human vascular smooth muscle cells express a constitutive nitric oxide synthase that insulin rapidly activates, thus increasing guanosine 3':5'-cyclic monophosphate and adenosine 3':5'-cyclic monophosphate concentrations. *Diabetologia*. 1999; 42:831–839. [PubMed: 10440125]
124. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. *J Clin Invest*. 1996; 97:2601–2610. [PubMed: 8647954]
125. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. *Rev Endocr Metab Disord*. 2010; 11:61–74. [PubMed: 20186491]
126. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. *J Clin Invest*. 2000; 105:311–320. [PubMed: 10675357]
127. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. *Circulation*. 2006; 113:1888–1904. [PubMed: 16618833]
128. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. *J Clin Invest*. 1995; 96:786–792. [PubMed: 7635973]
129. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. *J Clin Invest*. 2003; 111:1373–1380. [PubMed: 12727929]
130. Duncan ER, Crossey PA, Walker S, Anilkumar N, Poston L, Douglas G, Ezzat VA, Wheatcroft SB, Shah AM, Kearney MT. Effect of endothelium-specific insulin resistance on endothelial function in vivo. *Diabetes*. 2008; 57:3307–3314. [PubMed: 18835939]

131. Rask-Madsen C, Li Q, Freund B, Feather D, Abramov R, Wu IH, Chen K, Yamamoto-Hiraoka J, Goldenbogen J, Sotiropoulos KB, Clermont A, Gerald P, Dall'Osso C, Wagers AJ, Huang PL, Reikter M, Scalia R, Kahn CR, King GL. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. *Cell Metab.* 2010; 11:379–389. [PubMed: 20444418]
132. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. *Diabetes.* 2000; 49:684–687.
133. Czernichow S, Greenfield JR, Galan P, Jellouli F, Safar ME, Blacher J, Hercberg S, Levy BI. Macrovascular and microvascular dysfunction in the metabolic syndrome. *Hypertens Res.* 2010; 33:293–7. [PubMed: 20075933]
134. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. *Diabetes.* 2004; 53:2910–2920. [PubMed: 15504972]
135. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. *Diabetes.* 2001; 50:851–860. [PubMed: 11289052]
136. Fukumoto H, Naito Z, Asano G, Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. *J Atheroscler Thromb.* 1998; 5:29–35. [PubMed: 10077455]
137. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. *Circ Res.* 2001; 88:1291–1298. [PubMed: 11420306]
138. Han S, Liang CP, DeVries-Seimon T, Ranalletta M, Welch CL, Collins-Fletcher K, Accili D, Tabas I, Tall AR. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. *Cell Metab.* 2006; 3:257–266. [PubMed: 16581003]
139. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR. Increased CD36 protein as a response to defective insulin signaling in macrophages. *J Clin Invest.* 2004; 113:764–773. [PubMed: 14991075]
140. Welham MJ, Bone H, Levings M, Learmonth L, Wang LM, Leslie KB, Pierce JH, Schrader JW. Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells. *J Biol Chem.* 1997; 272:1377–1381. [PubMed: 8995447]
141. Bar RS, Gorden P, Roth J, Kahn CR, De Meyts P. Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting. *J Clin Invest.* 1976; 58:1123–1135. [PubMed: 993336]
142. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. *Am J Pathol.* 1996; 149:367–380. [PubMed: 8701977]
143. Hegyi L, Hardwick SJ, Mitchinson MJ, Skepper JN. The presence of apoptotic cells in human atherosclerotic lesions. *Am J Pathol.* 1997; 150:371–373. [PubMed: 9006352]
144. Kockx MM, Herman AG. Apoptosis in atherogenesis: implications for plaque destabilization. *Eur Heart J.* 1998; 19(Suppl G):G23–G28. [PubMed: 9717052]
145. Iida KT, Suzuki H, Sone H, Shimano H, Toyoshima H, Yatoh S, Asano T, Okuda Y, Yamada N. Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase-dependent pathway. *Arterioscler Thromb Vasc Biol.* 2002; 22:380–386. [PubMed: 11884278]
146. Helderman JH. Acute regulation of human lymphocyte insulin receptors. Analysis by the glucose clamp. *J Clin Invest.* 1984; 74:1428–1435. [PubMed: 6384270]
147. Stentz FB, Kitabchi AE. De novo emergence of growth factor receptors in activated human CD4+ and CD8+ T lymphocytes. *Metabolism.* 2004; 53:117–122. [PubMed: 14681852]
148. Helderman JH. Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte. *J Clin Invest.* 1981; 67:1636–1642. [PubMed: 6787080]

149. Masuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. *J Immunol.* 1992; 148:1367–1374. [PubMed: 1371526]
150. Walcher D, Aleksic M, Jerg V, Hombach V, Zieske A, Homma S, Strong J, Marx N. C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. *Diabetes.* 2004; 53:1664–1670. [PubMed: 15220188]
151. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. *Circulation.* 1996; 93:1809–1817. [PubMed: 8635260]
152. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. *Bmj.* 2000; 321:199–204. [PubMed: 10903648]
153. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? *Diabetologia.* 1998; 41:1241–1248. [PubMed: 9794114]
154. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation.* 2000; 102:42–47. [PubMed: 10880413]
155. Theuma P, Fonseca VA. Inflammation, insulin resistance, and atherosclerosis. *Metab Syndr Relat Disord.* 2004; 2:105–113. [PubMed: 18370641]
156. Dickhout JG, Basseri S, Austin RC. Macrophage function and its impact on atherosclerotic lesion composition, progression, and stability: the good, the bad, and the ugly. *Arterioscler Thromb Vasc Biol.* 2008; 28:1413–1415. [PubMed: 18650503]
157. Libby P. Inflammation in atherosclerosis. *Nature.* 2002; 420:868–874. [PubMed: 12490960]
158. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. *Jama.* 2004; 291:1978–1986. [PubMed: 15113816]
159. Song Y, Manson JE, Tinker L, Rifai N, Cook NR, Hu FB, Hotamisligil GS, Ridker PM, Rodriguez BL, Margolis KL, Oberman A, Liu S. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. *Diabetes.* 2007; 56:1898–1904. [PubMed: 17389327]
160. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest.* 2006; 116:1793–1801. [PubMed: 16823477]
161. Kim F, Gallis B, Corson MA. TNF-alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. *Am J Physiol Cell Physiol.* 2001; 280:C1057–C1065. [PubMed: 11287317]
162. Bierhaus A, Schiekofe S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. *Diabetes.* 2001; 50:2792–2808. [PubMed: 11723063]
163. Read MA, Whitley MZ, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. *J Exp Med.* 1994; 179:503–512. [PubMed: 7507507]
164. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. *Science.* 2001; 293:1673–1677. [PubMed: 11533494]
165. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, Kirk EA, Chait A, Schwartz MW. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. *Arterioscler Thromb Vasc Biol.* 2008; 28:1982–1988. [PubMed: 18772497]

Figure 1.

Insulin signaling. Insulin binds to its receptor causes a conformational change, autophosphorylation of the receptor, and activation of two pathways; The PI3K/Akt pathway leads to IRS tyrosine phosphorylation, which further phosphorylate PI3K subunit p85 and heterodimerization of p85 and p110. Akt activation upon the heterodimerization leads to PIP3 generation, which causes tyrosine phosphorylation/activation of PDK1; leading to serine phosphorylation/activation of Akt (also termed PKB). Activated Akt/PKB causes serine phosphorylation of eNOS/activation, rab-GTPase-activating protein-AS160, and HSL serine phosphorylation, inhibition of glycogen synthase kinase-3, threonine phosphorylation of S6K, and induction in Bcl-x gene expression; leading to NO generation, GLUT4 membrane translocation/glucose uptake, anti-lipolysis, glycogen synthesis, protein synthesis, and reduced-apoptosis. Exercise or insulin sensitizer adiponectin activates AMPK, which causes serine phosphorylation of IRS (at amino acid position 789- a positive regulation), eNOS (a positive regulation), and rab-GTPase-activating protein-AS160 and threonine phosphorylation of TSC1/2 (a negative regulation); leading to PI3K/Akt activation, NO production, glucose uptake, and protein synthesis inhibition. The MAPK cascade leads to activation of Ras signaling, cell proliferation, and inhibits apoptosis. IRS: insulin receptor substrate, PIP2: phosphatidylinositol 4,5-bisphosphate, PIP3: phosphatidylinositol 3,4,5-trisphosphate, PDK1: phosphoinositide-dependent kinase-1, PI3K: phosphatidylinositol 3-kinase, PKB: protein kinase B, eNOS: endothelial nitric oxide synthase, AS160: Akt substrate of 160 kDa, HSL: hormone sensitive lipase, S6K: ribosomal protein S6 kinase, NO: nitric oxide, GLUT4: glucose transporter4, AMP: adenosine monophosphate, ATP: adenosine triphosphate, AMPK: 5'-adenosine monophosphate-activated protein kinase, TSC1/2: tuberous sclerosis protein 1 and 2-tumor suppressor, Shc: sh2 domain-containing alpha-2 collagen-related protein, Grb2: growth factor receptor-bound protein 2, Sos: son of sevenless, MAPK: mitogen-activated protein kinase, MEK: mitogen-activated protein kinase kinase, Erk1/2: extracellular signal-regulated kinase1/2.

Figure 2.

PI3K/Akt pathway impairment is a key feature of IR and vascular dysfunction. Parallel and balanced insulin signaling between PI3K/Akt/eNOS and Ras/MAPK maintains normal vascular tone in healthy conditions. A variety of stimuli, including hyperglycemia, elevated FFA levels, cytokines, and others, increase production of ROS, RNS, and oxidative stress. These leads to activation of IKKbeta and other stress sensitive Ser/Thr kinases, which cause serine phosphorylation of IRS (at amino acid position 307-a negative regulation) and PI3K/Akt inhibition (IR effect). While PI3K/Akt/eNOS signaling is impaired, the Ras/MAPK pathway is less affected or even enhanced due to hyperinsulinemia, leading to reduce NO production and enhance ET-1 secretion, resulting in impaired vascular function. AMPK counteract the stress induced IR by serine phosphorylation of eNOS (a positive regulation) and IRS (at amino acid position 789-a positive regulation), which improves vascular function and IR. IR: insulin resistance, IRS: insulin receptor substrate, PI3K: phosphatidylinositol 3-kinase, eNOS: endothelial nitric oxide synthase, NO: nitric oxide, MAPK: mitogen-activated protein kinase, Erk1/2: extracellular signal-regulated kinase1/2, ET-1: endothelin-1, FFA: free fatty acid, ROS: reactive oxygen species, RNS: reactive nitrogen species, TNF-alpha: tumor necrosis factor-alpha, IKKbeta: inhibitor of nuclear factor kappa B kinase beta subunit, Ser/Thr: Serine/Threonine, VSMCs: vascular smooth muscle cells, AMPK: 5' adenosine monophosphate-activated protein kinase.

Figure 3. Mechanism of metabolic syndrome: A vicious circle. ECs: endothelial cells, VSMCs: vascular smooth muscle cells, MΦ: macrophages.